Convatec Group (FRA:2CVU) EBIT: €252 Mil (TTM As of Dec. 2025)


FRA:2CVU Convatec Group PLC FRA:2CVU
77 GF Score
Price €9.80
GF Value €11.76
! 4 Warning Signs
View Full Analysis

What is Convatec Group EBIT?

Convatec Group FRA:2CVU +2.62% 77 EBIT is €252 Mil as of Dec. 2025. GuruFocus rates FRA:2CVU with a GF Score™ of 77/100 and a GF Value™ of €11.76. The stock has 4 warning signs investors should review.

Convatec Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €107 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €252 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Convatec Group's annualized ROC % for the quarter that ended in Dec. 2025 was 9.33%. Convatec Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 24.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Convatec Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 4.16%.


Convatec Group  (FRA:2CVU) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Convatec Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=353.214 * ( 1 - 24.19% )/( (2840.552 + 2901.892)/ 2 )
=267.7715334/2871.222
=9.33 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3269.89 - 346.366 - ( 82.972 - max(0, 415.12 - 809.778+82.972))
=2840.552

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3228.974 - 269.01 - ( 58.072 - max(0, 526.064 - 802.76+58.072))
=2901.892

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Convatec Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=214.354/( ( (573.52 + max(325.038, 0)) + (656.726 + max(216.062, 0)) )/ 2 )
=214.354/( ( 898.558 + 872.788 )/ 2 )
=214.354/885.673
=24.20 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(349.054 + 330.414 + 47.338) - (346.366 + 0 + 55.402)
=325.038

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(278.404 + 355.264 + 86.254) - (269.01 + 0 + 234.85)
=216.062

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Convatec Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=251.532/6043.838
=4.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Convatec Group EBIT Related Terms


Convatec Group EBIT Historical Data

* Premium members only.

The historical data trend for Convatec Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Convatec Group EBIT Chart

Convatec Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 165.94 123.66 220.72 305.60 249.37

Convatec Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.32 130.90 171.04 144.36 107.18

FRA:2CVU vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Convatec Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Convatec Group EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Convatec Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Convatec Group's EV-to-EBIT falls into.


FRA:2CVU
77GF Score
Convatec Group PLC FRA:2CVU
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Convatec Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €252 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €252 Mil mean?
Convatec Group (FRA:2CVU) has a EBIT of €252 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Convatec Group.
Is Convatec Group's EBIT too high?
Convatec Group's current EBIT is €252 Mil. Overall, Convatec Group has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's EBIT compare to ISRG and BDX?
Convatec Group's EBIT of €252 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Convatec Group. Convatec Group's current EBIT is €252 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Convatec Group (FRA:2CVU) has a current EBIT of €252 Mil. The stock's GF Value™ is €11.76, compared to a current price of €9.80 — trading 16.7% below its estimated fair value. The current EBIT is €252 Mil. Convatec Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Convatec Group (FRA:2CVU), the current EBIT is €252 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Convatec Group (FRA:2CVU) Overvalued in 2026?

Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued. The current stock price of €9.80 is trading 16.7% below its estimated GF Value™ of €11.76.

Key valuation signals for FRA:2CVU:

  • EBIT: €252 Mil
  • GF Value™: €11.76 vs. price of €9.80 (16.7% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the FRA:2CVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Convatec Group Business Description

Address 20 Eastbourne Terrace, 7th Floor, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
77GF Score

Get the complete analysis for FRA:2CVU

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.80
Price
€11.76
GF Value